Biomarin Pharmaceutical Inc BMRN
BioMarin Pharmaceutical Inc. (BioMarin, we, us or our) is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. 10-K, Item 1
- Employees
- 3,221
- Headquarters
- Novato, CA
- CEO
- Alexander Hardy
- Next results
- around Jan 11, 2027
Where each dollar of revenue went, FY2025
Revenue of $3.2B through the costs to a net profit of $348.9M · income statement of the 10-K
BMRN among Health care peers
Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.
What changed
48 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Feb 26, 2026 against Feb 24, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
11 checks on the latest 10-K. Checks, not verdicts.
1fact worth reading about the other 10 checks found nothing to note
-
Receivables growing faster than revenueReceivables +37.5% ($660.5M to $908.2M) vs revenue +12.9% ($2.9B to $3.2B), +24.6 pts apart
-
Cash from operations $828.0M vs net income $348.9M (FY ending Dec 31, 2025)
9 more checks with nothing to note
-
Inventory +5.4% ($1.2B to $1.3B) vs revenue +12.9% ($2.9B to $3.2B), -7.5 pts apart
-
Same auditor in both 10-Ks: KPMG LLP
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
The same matters as last year: Evaluation of variable consideration relating to ALDURAZYME product sales
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
48 paragraphs in Risk Factors that were not in the 10-K filed Feb 24, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Feb 24, 2025 10-K, ITEM 1A
We have in the past and may in the future pursue acquisitions of other companies or businesses, which could divert our management’s attention, fail to achieve the anticipated benefits and/or expose us to other risks or difficulties. As part of our new corporate strategy, we have acquired, entered into agreements to acquire, and may…
-
Item 1A · new paragraph · not in the 10-K filed Feb 24, 2025 10-K, ITEM 1A
For example, we faced significant uncertainty as to whether gene therapy would gain the acceptance of the public or the medical community. In October 2025, we announced our plan to pursue options to divest ROCTAVIAN, including exploring out-licensing opportunities. Subsequently in December 2025, we committed to a plan to voluntarily…
-
Item 1A · new paragraph · not in the 10-K filed Feb 24, 2025 10-K, ITEM 1A
The pending Amicus Acquisition may not be completed on the currently contemplated timeline or terms, or at all. The consummation of the Amicus Acquisition is subject to the satisfaction or waiver of certain conditions. Satisfaction of a number of the conditions is not within our control, and it is possible that such conditions may…
-
Item 1A · new paragraph · not in the 10-K filed Feb 24, 2025 10-K, ITEM 1A
In connection with the pending Amicus Acquisition, some collaboration partners, vendors or other parties with commercial relationships with either of us or Amicus may delay or defer decisions, which could adversely affect the revenues, earnings, cash flows and expenses of us or Amicus, regardless of whether the Amicus Acquisition is…
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $2.1B | $2.4B | $2.9B | $3.2B |
| Net income | $141.6M | $167.6M | $426.9M | $348.9M |
| Operating cash flow | $175.9M | $159.3M | $572.8M | $828.0M |
| Free cash flow | $54.9M | $62.6M | $487.4M | $725.0M |
Revenue, FY2016 to FY2025
Ten fiscal years, each from its own 10-K · XBRL · USD
$3.2B ▲ 12.9% in FY2025$348.9M ▼ 18.3% in FY2025$725.0M ▲ 48.7% in FY2025
Recent filings
2 filings in the last 30 days · SEC EDGAR
-
10-QNov 3, 2026Quarterly report (10-Q) period ended Sep 30, 2026
-
8-KNov 2, 2026Quarterly results 8-K item 2.02
About the company
Biomarin Pharmaceutical Inc, Novato, CA · from the 10-K filed Feb 26, 2026
BioMarin Pharmaceutical Inc. (BioMarin, we, us or our) is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Our San Rafael, California-based company, founded in 1997, has a proven track record of innovation, with eight commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, we seek to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients.
- Headquarters
- Novato, CA
- Country
- United States
- Reports in
- USD
- Listed on
- Nasdaq
- Fiscal year ends
- December 31
- Last results
- Nov 2, 2026
- Incorporated in
- DE
Employees, at the top of the page: "As of December 31, 2025, we had 3,221 employees worldwide, of whom 1,518 were in operations, 692 were in research and development, 495 were in sales and marketing and 516 were in administration" (10-K). Address and exchange: SEC's company file.
Email alerts
Sources
The 10-K filed Feb 26, 2026 (open at SEC), compared with the 10-K filed Feb 24, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/BMRN/export.csv") into a cell.